recombinant pgrn protein  (Sino Biological)

Journal: Alzheimer's Research & Therapy

Article Title: Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease

doi: 10.1186/s13195-025-01817-4

Figure Lengend Snippet: Weekly dosing of AL101 in rats results in a chronic reduction of WBC cell surface sortilin levels and a parallel elevation of PGRN in serum and CSF. (A-C) Concentration-time profiles of sortilin cell surface levels in rat WBCs (A) and PGRN in rat serum (B) and CSF (C) . All data represent the mean ± SEM. Arrows indicate the timing of injections. For WBC sortilin, n = 3 to 6/group/time point; for serum PGRN, n = 5 to 6/group/time point; for CSF PGRN, n = 4 to 17/group/time point. Only the placebo and 300-mg/kg dose groups were included in the 6-week recovery phase. CSF, cerebrospinal fluid; PGRN, progranulin; SEM, standard error of the mean; WBC, white blood cell

Article Snippet: PGRN levels in plasma and CSF were determined via ELISA following manufacturer’s instructions (AdipoGen Life Sciences, Cat. #AG-45A-0043YEK-KI01) using a minimum required dilution (MRD) of 1:40 for plasma and 1:4 for CSF and with recombinant human PGRN (R&D Systems, Cat. #2420-PG) or equivalent as a calibrator.

Techniques: Concentration Assay

Journal: Alzheimer's Research & Therapy

Article Title: Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease

doi: 10.1186/s13195-025-01817-4

Figure Lengend Snippet: Multiple dosing of AL101 in cynomolgus monkeys decreases WBC cell surface sortilin levels and increases PGRN levels. (A-C) Concentration-time profiles of sortilin expression in monkey WBCs (A) and PGRN in monkey serum (B) and CSF (C) . Arrows indicate the timing of injections. Only the vehicle control and 200-mg/kg groups were included in the 6-week recovery phase. All data were normalized relative to predose baseline values (dashed lines) for each individual animal and are represented as the mean ± SEM. n = 4 to 10/group/time point. CSF, cerebrospinal fluid; PGRN, progranulin; SEM, standard error of the mean; WBC, white blood cell

Article Snippet: PGRN levels in plasma and CSF were determined via ELISA following manufacturer’s instructions (AdipoGen Life Sciences, Cat. #AG-45A-0043YEK-KI01) using a minimum required dilution (MRD) of 1:40 for plasma and 1:4 for CSF and with recombinant human PGRN (R&D Systems, Cat. #2420-PG) or equivalent as a calibrator.

Techniques: Concentration Assay, Expressing, Control

Journal: Alzheimer's Research & Therapy

Article Title: Development of AL101 (GSK4527226), a progranulin-elevating monoclonal antibody, as a potential treatment for Alzheimer’s disease

doi: 10.1186/s13195-025-01817-4

Figure Lengend Snippet: SD and MD AL101 administration increases PGRN levels. (A-B) Mean (± standard deviation) percentage change from baseline of plasma PGRN vs. time for SD (A) and MD (B) cohorts. Color-coded arrows indicate dosing days for the IV and SC MD cohorts (B) . (C) Mean (± standard deviation) percentage change from baseline in CSF PGRN concentrations vs. time for all cohorts. For plasma PGRN, n = 1 to 13/group/time point, and for CSF PGRN, n = 1 to 10/group/time point. For plasma PGRN, n < 3 for the MD IV placebo group at multiple time points; for CSF PGRN, n < 3 for the SD IV placebo (Day 57), 6-mg/kg SD IV AL101 (Day 25), 30-mg/kg SD IV AL101 (Day 85), 600-mg SD SC AL101 (Day 43), and MD IV placebo groups (Days 97 and 113). CSF, cerebrospinal fluid; IV, intravenous; MD, multiple dose; PGRN, progranulin; SC, subcutaneous; SD, single dose

Article Snippet: PGRN levels in plasma and CSF were determined via ELISA following manufacturer’s instructions (AdipoGen Life Sciences, Cat. #AG-45A-0043YEK-KI01) using a minimum required dilution (MRD) of 1:40 for plasma and 1:4 for CSF and with recombinant human PGRN (R&D Systems, Cat. #2420-PG) or equivalent as a calibrator.

Techniques: Standard Deviation, Clinical Proteomics